Results 51 to 60 of about 15,210 (229)
Clinical and Translational Science, 2021 Reduced expression of the uptake transporter, OCTN1 (SLC22A4), has been reported as a strong predictor of poor event‐free and overall survival in multiple cohorts of patients with acute myeloid leukemia (AML) receiving the cytidine nucleoside analog ...
Daelynn R. Buelow +9 more
doaj +1 more source
Decitabine in the treatment of acute myeloid leukemia in elderly patients [PDF]
, 2014 Priya Malik, Amanda F CashenWashington University School of Medicine, St Louis, MO, USAAbstract: The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy. Decitabine, a DNA-hypomethylating
Cashen, Amanda F., Malik, Priya
core +3 more sources
Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials
iNew Medicine, EarlyView.ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong +5 more
wiley +1 more source
How I treat MDS after hypomethylating agent failure [PDF]
Blood, 2019 Abstract Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for myelodysplastic syndrome (MDS). Response to these agents occurs in ∼50% of treated patients, and duration of response, although variable, is transient.
openaire +3 more sources
Journal of Clinical Laboratory Analysis, EarlyView.Inhibition of XPO1 is a promising modality in the treatment of MDS, especially when combined with Venetoclax, which activates mitochondria‐mediated apoptosis and could be a potential target for MDS therapy. ABSTRACT Background Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies that pose a serious health threat.
Xiaohan Liu +8 more
wiley +1 more source
Hypomethylating agents use in acute myeloid leukemia: A single-center experience
Indian Journal of Medical and Paediatric Oncology, 2020 Context: Acute myeloid leukemia (AML) is a heterogeneous disease. Approximately 80% of older AML patients will die of their disease or its treatment with currently available antileukemic therapy because of the adverse prognostic risk factors.
Sravan Kumar Bodepudi +5 more
doaj +1 more source
Case Reports in Hematology, 2021 Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using ...
Di Wu +3 more
doaj +1 more source
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers [PDF]
, 2016 The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other ...
Buschbeck, Marcus +5 more
core +2 more sources
JEADV Clinical Practice, EarlyView.ABSTRACT Differentiation syndrome (DS) and Sweet syndrome (SS) are inflammatory complications mediated by cytokine dysregulation, classically associated with therapies that promote myeloid differentiation or cytokine release. While DS has been primarily linked to all‐trans retinoic acid (ATRA) and IDH inhibitors, recent evidence suggests that ...
Katerina Grafanaki +6 more
wiley +1 more source
Nature Communications, 2023 Hypomethylating agents, such as 5-Azacytidine (5-AZA), are standard of care for patients with myelodysplastic and myeloid malignancies, however response rates are limited and risk of relapses high.
Qingyu Xu +31 more
doaj +1 more source